Recent News
If you are aware of any news items that would be of interest to the RQA membership, please contact the RQA office.
-
Falsified Medicines and the supply chain
13th August 2019MHRA Blog post by Tracy Moore, 8th August.
Read More+ -
MHRA Update to regulations if there is a no deal Brexit
13th August 2019Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal - Updated 8 August 2019
Read More+ -
Protecting Public Health - Article
13th August 2019Dr Ian Hudson, CEO, Medicines and Healthcare products Regulatory Agency (MHRA) spoke with Viveka Roychowdhury on how the Agency is working with pharmaceutical companies to increase compliance with Good Manufacturing Practices (GMP) as well as preparing for Brexit and beyond. Read the full article.
Read More+ -
Updated - Blue Guide: advertising and promoting medicines
13th August 2019Detailed guidance on advertising and promoting medicines - updated 12th August 2019.
Read More+ -
EMA Update - What’s new in Pharmacovigilance?
12th August 2019The first edition of the EMA's 'What’s new in Pharmacovigilance? QPPV UPDATE' is available.
Read More+ -
Electronic Health Records
7th August 2019New MHRA Blog Post on eHRs: as you will be aware, in the UK there is a national NHS initiative to replace patients’ paper medical records with electronic health records (EHRs). Although a national initiative, trusts are implementing this locally with different service providers. At several trusts this consists of scanning all written records into the EHR and destroying original source documents (both historic records and current visits).
Read More+ -
BP and USP MoU formalise partnership
31st July 2019BP and USP MoU formalise partnership to strengthen quality of medicines and public health
Read More+ -
EMA publishes Draft on Quality Requirements for Combination Products
31st July 2019The European Medicines Agency (EMA) has published a draft guideline on quality requirements for combinations of medicinal products and medical devices (so-called Drug Device Combinations - DDCs).
Read More+ -
Supporting medicine developers in generating quality data packages
31st July 2019Supporting medicine developers in generating quality data packages in early access approaches (PRIME and breakthrough therapies): workshop report published
Read More+ -
OECD Update to the Principles of GLP
29th July 2019The OECD recently released document 20 in the GLP series: Guidance Document for Receiving Authorities on the Review of the GLP Status of Non-Clinical Safety Studies.
Read More+ -
MHRA Update on a No Deal Brexit
26th July 2019The Human Medicines and Medical Devices (Amendment etc.) (EU exit) Regulations 2019 was laid in UK parliament on the 24th July 2019.
Read More+ -
EMA Public Engagement Highlights of 2018
25th July 2019The EMA recently shared the highlights of patient, consumer, healthcare professional and academia involvement in our activities in 2018 with the RQA.
Read More+ -
CVMP meeting, 16-18 July 2019
24th July 2019Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16-18 July 2019
Read More+ -
EMA takes note of the European Ombudsman’s decision on pre-submission activities
24th July 2019EMA welcomes the European Ombudsman’s recognition of the value and need for scientific advice and her recommendations are in line with EMA’s ongoing initiatives to further increase transparency.
Read More+ -
Government to invest £16m in ‘life-saving’ medical advances
24th July 2019The Government has announced the decision to invest around £16 million in various ‘life-saving’ medical advances, including improved diagnosis and treatment for cancer and heart disease.
Read More+ -
EU and US reach a milestone....
15th July 2019With the recognition by the US Food and Drug Administration (FDA) of Slovakia, the European Union and the United States have now fully implemented the mutual recognition agreement (MRA) for inspections of manufacturing sites for certain human medicines in their respective territories.....
Read More+ -
Updated Version of the Clinical Trials Regulation Questions & Answers Paper
11th July 2019Updated Version of the Clinical Trials Regulation Questions & Answers Paper
Read More+ -
GPvP - FDA issues final guidance for Industry on Risk Evaluation and Mitigation Strategies: Modifications and Revisions
10th July 2019Today, the U.S. Food and Drug Administration (FDA) issued a final guidance for industry entitled Risk Evaluation and Mitigation Strategies: Modifications and Revisions.
Read More+ -
European Commission - Withdrawal of the UK and EU rules in the field of GLP
1st July 2019The United Kingdom submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union.
Read More+ -
MHRA public consultation on its plans to apply analytical quality by design (AQbD) principles to its Pharmacopoeia
12th June 2019The MHRA opened a three-month public consultation (until August 31, 2019) on its plans to apply analytical quality by design (AQbD) principles to its pharmacopoeia.
Read More+ -
MHRA - GCP Serious Breaches - the 2018 Edition
3rd June 2019MHRA's GCP Serious Breaches metrics and examples have been released.
Read More+ -
GOOD STORAGE AND DISTRIBUTION PRACTICES
29th May 2019WHO Document for Consultation GOOD STORAGE AND DISTRIBUTION PRACTICES
Read More+ -
MHRA STEM Minutes
29th May 2019Minutes and presentations now available.
Read More+ -
Brexit: EU supports pharmaceutical Companies
6th March 2019Medicinal products imported into the EU must undergo batch testing within the EU and the European Economic Area (EEA)*. Once the United Kingdom (UK) leaves the EU (Brexit), pharmaceutical manufacturers who have previously carried out batch testing in the UK must relocate their batch testing operations to the EU/EEA in order to import their products.
Read More+ -
Brexit: Handling PV Data from the UK
6th March 2019The European Medicines Agency (EMA) has updated the agency's Brexit-related guidance documents. This guidance is supporting pharmaceutical companies to prepare for the United Kingdom's (UK) withdrawal from the European Union (EU). Now the 'Questions and Answers' document has been updated (Rev 04, published on 1st February 2019). The new Q&As address the situation when the United Kingdom becomes a third country on 30th March 2019 without a withdrawal agreement (and hence without a transition period).
Read More+ -
Brexit-related guidance for companies
25th February 2019The European Medicines Agency (EMA) and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the United Kingdom's (UK) withdrawal from the European Union (EU), a process known as 'Brexit'.
Read More+
